SCL Healthcare Unveils Multi-Cancer Early Detection Tech at ASCO

SCL Healthcare showcased its advanced research and services at the ASCO 2026 conference, one of the world's largest oncology gatherings. The company highlighted its expertise in clinical trial analysis and artificial intelligence-driven cancer diagnostics, aiming to solidify its position as a key partner in global drug development.

At the event, held in Chicago from May 29 to June 2, SCL Healthcare focused on its Central Lab (C-LAB) and Companion Diagnostic Biomarker (CB) center. C-LAB presented its pharmacokinetic analysis services, particularly for antibody-drug conjugates (ADCs), and its expanded capabilities in mass spectrometry analysis. These services are crucial for new drug development, especially for complex treatments like ADCs and peptide drugs.

“

We will strengthen our competitiveness in digital healthcare, including AI diagnostics, and expand our role as a global new drug development partner.

The CB center shared its research achievements, spanning biomarker discovery to clinical application. This included a Korean model for homologous recombination deficiency (HRD) gene testing for ovarian cancer treatment response and an AI technology for early cancer detection based on platelet genomic data. The company also revealed ongoing research to extend its multi-cancer early detection (MCED) technology to minimal residual disease (MRD) analysis.

Baek Se-yeon, COO of SCL Healthcare, expressed the significance of participating in ASCO for five consecutive years, emphasizing the opportunity to introduce their capabilities to the global market. "We will strengthen our competitiveness in digital healthcare, including AI diagnostics, and expand our role as a global new drug development partner," she stated. SCL Healthcare plans to sequentially release further data on its MCED research.

“

Currently preparing additional data related to MCED. We plan to sequentially release related research findings.